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as a 3-h or a 24-h infusion in combination with carboplatin and
etoposide in patients with extensive-stage small cell lung cancer
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DS Subramaniam9, J Schnyder10 and MS Berger10
1H. Lee Moff itt Cancer Center and Research Institute, Thoracic Oncology Program, FOB1, Room 5.111, 12902 Magnolia Drive, Tampa, FL 33612,
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Translational Oncology Research, Greenville, SC 29605, USA; 5The West Clinic, Memphis, TN 38120, USA; 6Department of Medicine, Section of
Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA; 7Department of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta,
Canada T6G 1Z2; 8Mayo Clinic Arizona, Scottsdale, AZ 85259, USA; 9Department of Internal Medicine, Division of Hematology-Oncology, Georgetown
University, Washington, DC 20007, USA; 10Gemin X Pharmaceuticals, Malvern, PA 19355, USA
BACKGROUND: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate
the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy.
METHODS: Eligible patients (3–6 per cohort) had extensive-stage SCLC, measurable disease,p1 before therapy, Eastern Cooperative
Oncology Group performance status 0 or 1, and adequate organ function. Patients were treated with escalating doses of obatoclax,
either as a 3- or 24-h infusion, on days 1–3 of a 21-day cycle, in combination with carboplatin (area under the curve 5,
day 1 only) and etoposide (100 mg m2, days 1–3). The primary endpoint was to determine the maximum tolerated dose of
obatoclax.
RESULTS: Twenty-five patients (56% male; median age 66 years) were enrolled in three dose cohorts for each schedule. Maximum
tolerated dose was established with the 3-h infusion at 30 mg per day and was not reached with the 24-h infusion. Compared with
the 24-h cohorts, the 3-h cohorts had higher incidence of central nervous system (CNS) adverse events (AEs); dose-limiting toxicities
were somnolence, euphoria, and disorientation. These CNS AEs were transient, resolving shortly after the end of infusion, and
without sequelae. The response rate was 81% in the 3-h and 44% in the 24-h infusion cohorts.
CONCLUSION: Although associated with a higher incidence of transient CNS AEs than the 24-h infusion, 3-h obatoclax infusion
combined with carboplatin–etoposide was generally well tolerated at doses of 30 mg per day. Though patient numbers were small,
there was a suggestion of improved efficacy in the 3-h infusion group. Obatoclax 30 mg infused intravenously over 3 h on 3
consecutive days will be utilised in future SCLC studies.
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Small cell lung cancers (SCLCs) account for approximately 13%
of all lung cancer cases (Govindan et al, 2006), and two-thirds of
patients with SCLC have extensive stage (ES) disease and are not
considered to be curable. Despite initial tumour chemosensitivity,
median survival for patients with ES-SCLC is 7 to 10 months, and
the 2-year survival rate is o5% (Thatcher et al, 2005) due to
frequent relapse with metastatic and/or chemoresistant disease.
Platinum-based chemotherapy (cisplatin or carboplatin) com-
bined with etoposide is generally recommended as the initial
therapy (Spira and Ettinger, 2004; also see NCCN Guidelines
at www.nccn.org). Four to six cycles of this combination are
considered optimal (Thatcher et al, 2005). Because brain
metastases are common in patients with ES-SCLC, prophylactic
cranial irradiation is generally recommended in patients with
ES-SCLC who achieve a response to systemic chemotherapy to
prolong median overall survival (Slotman et al, 2007).
BCL-2 family proteins are frequently (65–80%) expressed in
SCLC (Ben-Ezra et al, 1994; Jiang et al, 1995), and Bcl-2 family
genes are frequently amplified in SCLC cell lines (Beroukhim et al,
2010). Furthermore, SCLC cell lines are sensitive to inhibition of
the pro-survival members of the BCL-2 family (Shoemaker et al,
2008; Dean et al, 2011). Thus, inhibiting the BCL-2 pro-survival
proteins may be a useful strategy in the treatment of SCLC.
Obatoclax mesylate (GX15-070MS) is a small molecule that
antagonises pro-survival members of the BCL-2 family of proteins
by binding the BH3-binding groove and blocking interaction with
pro-apoptotic family members. Obatoclax inhibits all BCL-2
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pro-survival family members, including MCL-1 (Nguyen et al,
2007; Warr and Shore, 2008). It has been shown to activate
apoptosis in vitro (Nguyen et al, 2007) to exhibit antitumour
activity in animal models (Nguyen et al, 2007; Smoot et al, 2010),
and to enhance the effects of chemotherapeutic agents, including
cisplatin and etoposide, in SCLC cell lines in vitro (Dean et al,
2011). It has previously shown single-agent biological and clinical
activity in phase I studies in other, mainly haematological,
malignancies (Schimmer et al, 2008; O’Brien et al, 2009).
Obatoclax may be associated with infusional central nervous
system (CNS) toxicities such as somnolence, euphoric mood, and
ataxia (O’Brien et al, 2009; Hwang et al, 2010). These toxicities may
be mediated by inhibition of BCL-XL, a protein that regulates
nerve cell synaptic plasticity (Hickman et al, 2008). In previous
studies, the intensity of infusional CNS toxicities decreased as the
infusion duration increased from 1 h to 3 h (Hwang et al, 2010),
and were even less prominent with longer (24-h) infusions
(Schimmer et al, 2008).
The safety of the 3-h versus the 24-h infusion schedules has been
compared in only one small trial, in older patients, with previously
untreated acute myeloid leukemia (Raza et al, 2009). Therefore,
this study compared the safety and tolerability of the 3-h and
the 24-h infusions of obatoclax, combined with carboplatin and
etoposide in patients with ES-SCLC.
PATIENTS AND METHODS
This was an open-label, phase I trial conducted at nine institutions
in North America (ClinicalTrials.gov Number NCT00682981).
The protocol was approved by the Institutional Review Boards of
all participating centres. Informed consent was obtained from
all patients before enrolment, in accordance with the Declaration
of Helsinki.
Trial design
The primary objective of this phase I study was to determine the
maximum tolerated dose (MTD) and the recommended phase II
dose of obatoclax, administered as either a 3-h or a 24-h infusion,
when combined with carboplatin and etoposide in patients
with ES-SCLC. The secondary objective was to characterise the
safety profile of each schedule. Efficacy data for each schedule were
also preliminarily assessed.
Three to six patients were enrolled into ascending-dose cohorts.
Enrolment alternated between infusion schedules, starting with the
lowest 3-h infusion cohort, which was filled before enrolment
moved to the lowest 24-h infusion cohort. Planned obatoclax
dosage groups were 15, 30, and 45 mg per day with the 3-h
infusion, and 30, 45, and 60 mg per day with the 24-h infusion.
In each case, the highest dose planned was the single-agent
MTD established by previous studies (45 and 60 mg per day,
respectively).
Obatoclax was administered first (or, for the 24-h infusion
cohort, initiated first), followed by an intravenous infusion of
carboplatin (area under the curve 5; day 1 only) and of etoposide
(100 mg m2; days 1, 2, and 3), repeated on a 21-day cycle.
Obatoclax was administered on days 1 –3 to suppress the activity
of the BCL-2 family pro-survival proteins during all days of the
cytotoxic chemotherapy administration.
Patients received combination cytotoxic chemotherapy treat-
ment for six cycles in the absence of disease progression or
intolerable toxicity. Initially, prophylaxis with diphenhydramine
and an H2 antagonist was recommended before the administration
of obatoclax to prevent cytokine release syndrome. After
diphenhydramine was found to exacerbate the infusional somno-
lence, the protocol was amended to utilise only an H2 antagonist.
All patients who achieved an objective response (complete
or partial) with combination chemotherapy were to receive
prophylactic cranial irradiation. Patients who remained without
progression after chemotherapy were to receive single-agent
obatoclax as maintenance therapy every 21 days, using the same
dose and schedule administered to that patient during the
combination therapy. Maintenance therapy was administered until
the occurrence of disease progression or intolerable toxicity. For
patients receiving prophylactic cranial irradiation, obatoclax
maintenance therapy was not initiated until at least 2 weeks after
completion of prophylactic cranial irradiation.
Patients were assessed on the first day of each cycle for the
presence of adverse events (AEs). This assessment included a full
history and physical examination (emphasising the presence or
occurrence of any toxicities), and laboratory blood work, including
haematological and biochemical testing. Adverse events occurring
during cycle 1 were used to identify dose-limiting toxicities (DLTs)
before dose escalation.
For haematological toxicities, DLT was defined as a grade
4 neutropenia with fever, grade 4 neutropenia without fever forX7
days, or grade 4 thrombocytopenia. Grade 3 or 4 non-hematolo-
gical toxicity not ameliorated by supportive therapy was also
defined as a DLT. The MTD was defined as the dose level before
the obatoclax dose where two out of six DLTs were observed.
Per protocol, the MTD was also considered the recommended
phase II dose.
In patients who experienced grade 4 neutropenia, prophylactic
growth factor support was recommended in subsequent cycles. For
grade 4 neutropenia despite growth factor prophylaxis, or in the
case of grade 4 thrombocytopenia, the dose of etoposide was
reduced to 80 mg m2, and the dose of carboplatin was reduced to
area under the curve 4. For all other grade 3 or 4 AEs unresponsive
to supportive care, the dose of obatoclax was reduced by 15 mg per
day. Treatment was delayed in patients whose absolute neutrophil
count and platelet count had not recovered to X1500/mm3 and
X100 000/mm3, respectively, by the start of the next cycle.
Recurrence of toxicity following one dose reduction or a delay in
therapy beyond 2 weeks resulted in discontinuation of treatment.
Patients
Eligible patients were X18 years old, with pathological or
cytological confirmation of SCLC and with disease sites consistent
with ES-SCLC. Eligibility required measurable disease as defined
by the Response Evaluation Criteria in Solid Tumors (RECIST)
v1.0 (Therasse et al, 2000), as well as the Eastern Cooperative
Oncology Group (ECOG) performance status p1 at baseline.
Patients with platinum-sensitive relapsed disease were initially
allowed. However, the trial was amended to include only
chemotherapy-naı¨ve patients after previously treated patients were
noted to have a greater degree of myelosuppression. Enrolled
patients also had to have normal organ function defined as
absolute neutrophil count X1500/mm3, platelets X100 000/mm3,
total bilirubin pupper limit of normal or total bilirubin
p3.0 mg dl1 if liver metastases were present, alanine amino-
transferase (serum glutamic pyruvic transaminase) p2.5 upper
limit of normal, or alanine aminotransferase (serum glutamic
pyruvic transaminase) p5 upper limit of normal if liver
metastases were present, and creatinine within normal limits. A
negative pregnancy test result was required for women of
childbearing potential, and both women and men had to use a
highly effective method of birth control.
Patients with a history of seizure disorders unrelated to SCLC
brain metastases or with symptomatic brain metastases were
excluded, as were patients who were pregnant or breast feeding.
Safety and efficacy
Adverse events were graded according to the NCI CTCAE version
3.0. (see http://ctep.cancer.gov/reporting/ctc.html). A computerised
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tomography or magnetic resonance imaging scan of the brain was
obtained at the pre-study visit. Tumour evaluations were documen-
ted by either computerised tomography scan with intravenous
contrast or magnetic resonance imaging within 21 days of the start of
treatment and repeated every other cycle, at the end of treatment
visit, and every 6 weeks until progression. Best overall response was
assessed using the RECIST v1.0 criteria (Therasse et al, 2000).
Complete response, partial response, and stable disease were
confirmed by a second evaluation at least 4 weeks later.
RESULTS
Patients and exposure
Twenty-five patients (median age of 66 years, 56% (n¼ 14) male)
were enrolled. The ECOG performance status was 0 for 6 patients
and 1 for 19 patients. Eighteen of the enrolled patients were
chemotherapy-naı¨ve (Table 1). Patients received a median of
six combination chemotherapy cycles (range, 2– 6), with all six
planned treatment cycles completed by 20 patients (80%; 16 in the
3-h infusion group, and 4 in the 24-h infusion group). Twelve
patients (8 in the 3-h infusion group, and 4 in the 24-h infusion
group) went on to receive a median of two (range, 1 –24) cycles of
maintenance therapy with the single-agent obatoclax. The most
common reason for discontinuation was disease progression
(n¼ 18 (72%)); other reasons for discontinuation included
AEs (n¼ 3; grade 3 or 4 thrombocytopenia in all three cases),
withdrawal by patient (n¼ 2), and other (n¼ 1). The median
duration of treatment was similar for patients on the 3-h infusion
schedule (118 days) and patients on the 24-h infusion schedule
(115 days). Of the 138 total cycles administered, obatoclax
treatment was delayed, interrupted, or discontinued in 22% of
cycles (n¼ 30) due to AE, and in an additional 9% (n¼ 13) due to
other reasons; rates of delay/interruption/discontinuation were
similar in the 3-h vs the 24-h infusion groups. Obatoclax dose
reductions were necessary in four patients, all of whom were in the
45 mg per day, 3-h infusion group.
Dose escalation and MTD
Patients were enrolled into six dosing cohorts. The ‘ping-pong’
enrolment alternatively filled cohorts in the 3-h and the 24-h
dosing schedules (Figure 1).
In the 3-h infusion arm, no DLTs were observed in the initial
cohort treated with obatoclax 15 mg per day. DLT occurred in two
patients in the cohort who received obatoclax 30 mg per day over
3 h; in both cases, DLT consisted of myelosuppression in
previously treated patients. As a result, the trial was amended to
exclude previously treated patients. Five previously untreated
patients receiving obatoclax 30 mg per day over 3 h had no DLTs.
DLT was observed in two out of six patients who received
obatoclax 45 mg over 3 h (somnolence and euphoria, and
somnolence and disorientation), establishing the MTD for
obatoclax at 30 mg over 3 h for 3 consecutive days (recommended
phase II dose).
No DLTs were observed in the patients receiving treatment in
the 24-h infusion arm. However, two patients in the obatoclax 24-h
infusion cohorts (one at 30 mg per day and another at 45 mg per
day) had infusion pump malfunctions while at home. As a result,
safety data for these two patients were excluded from the data used
for deciding dose escalation. Furthermore, patient safety con-
siderations associated with the potential inaccuracy in the delivery
of the obatoclax dose due to pump malfunctions led to early
discontinuation of the 60 mg over 24-h dosing cohort. Only one
patient was entered in this cohort (this patient had already been
enrolled when the decision to discontinue this cohort was made),
with no reported DLTs.
Table 1 Demographic data
3-h infusion 24-h infusion Total
Obatoclax dose (mg per day) 15 30 45 30 45 60 —
Number of patients 3 7 6 4 4 1 25
Median age, years (range) 72 (67–75) 65 (53–70) 64 (57–74) 65 (61–69) 70 (65–75) 53 (53) 66 (53–75)
Males 1 3 4 4 2 0 14
ECOG PS
0 2 1 2 1 0 0 6
1 1 6 4 3 4 1 19
Chemotherapy-naı¨ve 1 5 6 3 2 1 18
Abbreviation: ECOG PS¼ Eastern Cooperative Oncology Group performance status.
24 h, 60 mg per day
n =1§
No DLT
3 h, 45 mg per day
n =6
DLT in 2 patients
24 h, 45 mg per day
n =4*
No DLT
24 h, 30 mg per day
n =4*
No DLT
3 h , 30 mg per day
n =7
No DLT†
3 h, 15 mg per day
n =3
No DLT
Figure 1 Enrolment into dosing cohorts. A total of 25 patients were
enrolled, alternating between 3-h and 24-h infusion cohorts. wNo DLT
observed in five treatment-naı¨ve patients in this cohort. Myelosuppressive
DLT observed in two previously treated patients; protocol was amended
to exclude previously treated patients and these DLTs were excluded from
dose-escalation decision. *Safety data from one patient excluded
from dose-escalation decision due to pump malfunction. yThis cohort
was discontinued after enrolment of one patient.
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Safety data
The most common AEs reported in the study included neutropenia
(96%), thrombocytopenia (76%), anaemia (72%), fatigue (68%),
and nausea (52%; Table 2). To highlight differences in the safety
profile between the 3-h and the 24-h obatoclax infusions,
differences in the incidence of non-haematological AEs between
the two groups were evaluated (Table 3). CNS AEs (somnolence,
euphoric mood, insomnia, and ataxia) occurred at a lower
incidence in the 24-h obatoclax infusion group.
Grade 3 and 4 AEs that occurred in two or more patients are
displayed in Table 4. Grade 3 or 4 haematological AEs occurring in
all patients during the study included neutropenia (75% in 3-h vs
89% in 24-h), thrombocytopenia (44 vs 33%), anaemia (25 vs 22%),
and leukopenia (19 vs 0%). These data do not indicate large
differences in myelosuppression between the obatoclax infusion
groups. Non-haematological grade 3 and 4 AEs that occurred with
a X10% increase in incidence in either obatoclax infusion group
did not exhibit a clear pattern suggestive of toxicity in a particular
organ system (Table 3).
Grade 3 or 4 CNS or psychiatric AEs that occurred in this study
all occurred in the 3-h obatoclax infusion cohorts. These were
grade 3 somnolence in five patients (31% of the 3-h cohort
patients), grade 3 syncope in one patient (6%), grade 4 confusional
state in one patient (6%), grade 3 depression in one patient (6%),
grade 3 euphoric mood in one patient (6%), grade 3 mental status
changes in one patient (6%), and grade 3 mood altered in one
patient (6%). The majority of these CNS or psychiatric AEs
occurred during the obatoclax infusion and resolved shortly after
the infusion ended (within the 1-h post-infusion observation
period mandated by the protocol). Diphenhydramine appeared to
exacerbate the infusional somnolence in some patients. Once this
was recognised, the protocol was amended and diphenhydramine
was no longer administered prophylactically.
One patient experienced grade 2 cytokine release syndrome. On
the first day of cycle 2, after premedication with diphenhydramine
and an H2 antagonist, this patient experienced back pain and facial
flushing B0.5 h after the start of the infusion. The infusion was
stopped, and the patient was given additional diphenhydramine.
The infusion was re-started, and the patient had no further
cytokine release syndrome symptoms through the three additional
cycles of the obatoclax treatment that were administered.
Serious AEs were reported in 13 patients (52%; 9 in the 3-h
infusion group and 4 in the 24-h infusion group) and consisted of
anaemia (n¼ 2), neutropenia (n¼ 2), and nausea (n¼ 2), and
n¼ 1 each of febrile neutropenia, thrombocytopenia, abdominal
pain, diarrhoea, oesophagitis, vomiting, chronic obstructive
pulmonary disease, hypoxia, pulmonary embolism, labyrinthitis,
hyponatremia, syncope, confusional state, and deep vein throm-
bosis. The incidence of blood and lymphatic system and
respiratory disorders reported as serious AEs was similar for the
two infusion schedules; GI serious AEs were only reported for
patients on the 3-h infusion schedule.
No deaths occurred within 30 days of study treatment. In one
patient, treated at the 30 mg per day obatoclax dose level on the
24-h infusion schedule, the AE that led to death was reported
as possibly treatment related. This patient received six cycles of
treatment before discontinuation due to disease progression; the
patient developed grade 2 lung collapse 69 days post-treatment and
died approximately 1 month later with the cause of death reported
as respiratory failure.
Clinical efficacy
Table 5 represents the efficacy results for the intent-to-treat
population. The overall response rate was 68% (81 vs 44% in the 3-
h and the 24-h infusion cohorts, respectively). Median progres-
sion-free survival in both cohorts was similar, but it was observed
that several patients in the 3-h cohorts had considerably longer
progression-free survival. The median overall survival was
numerically higher in patients who received obatoclax by 3-h
infusion (379 vs 283 days).
Among chemotherapy-naı¨ve patients, the overall response rate
was 83% (15 out of 18), with responses demonstrated in all patients
in the 3-h infusion group (n¼ 12; 2 complete and 10 partial)
and 50% of patients in the 24-h infusion group (3 out of 6; all
partial responses). Among the seven patients enrolled who had
previously received a platinum-based cytotoxic chemotherapy
regimen, three achieved a partial response (one of which was not
confirmed). For these three patients, the time between the end of
their initial treatment and the start of treatment in this study was
4.5, 6, and 17.7 months. Two were previously treated with
carboplatin and etoposide, and one with cisplatin and etoposide.
Table 2 Most common adverse events (X25%) at all toxicity grades
3-h infusion schedule, n (%) 24-h infusion schedule, n (%) Total, n (%)
Preferred term
Obatoclax
15mg
per day
(n¼ 3)
Obatoclax
30mg
per day
(n¼ 7)
Obatoclax
45mg
per day
(n¼ 6)
Overall
(n¼ 16)
Obatoclax
30mg
per day
(n¼ 4)
Obatoclax
45mg
per day
(n¼4)
Obatoclax
60mg
per day
(n¼1)
Overall
(n¼ 9) (N¼ 25)
Neutropenia 3 (100.0) 6 (85.7) 6 (100.0) 15 (93.8) 4 (100.0) 4 (100.0) 1 (100.0) 9 (100.0) 24 (96.0)
Thrombocytopenia 3 (100.0) 6 (85.7) 4 (66.7) 13 (81.3) 1 (25.0) 4 (100.0) 1 (100.0) 6 (66.7) 19 (76.0)
Anaemia 3 (100.0) 5 (71.4) 4 (66.7) 12 (75.0) 1 (25.0) 4 (100.0) 1 (100.0) 6 (66.7) 18 (72.0)
Fatigue 2 (66.7) 4 (57.1) 6 (100.0) 12 (75.0) 1 (25.0) 3 (75.0) 1 (100.0) 5 (55.6) 17 (68.0)
Nausea 2 (66.7) 3 (42.9) 4 (66.7) 9 (56.3) 2 (50.0) 1 (25.0) 1 (100.0) 4 (44.4) 13 (52.0)
Alopecia 0 5 (71.4) 4 (66.7) 9 (56.3) 1 (25.0) 1 (25.0) 1 (100.0) 3 (33.3) 12 (48.0)
Constipation 3 (100.0) 3 (42.9) 3 (50.0) 9 (56.3) 1 (25.0) 1 (25.0) 1 (100.0) 3 (33.3) 12 (48.0)
Somnolence 1 (33.3) 7 (100.0) 4 (66.7) 12 (75.0) 0 0 0 0 12 (48.0)
Anorexia 2 (66.7) 3 (42.9) 2 (33.3) 7 (43.8) 1 (25.0) 1 (25.0) 1 (100.0) 3 (33.3) 10 (40.0)
Dizziness 2 (66.7) 2 (28.6) 1 (16.7) 5 (31.3) 1 (25.0) 2 (50.0) 1 (100.0) 4 (44.4) 9 (36.0)
Dehydration 2 (66.7) 2 (28.6) 2 (33.3) 6 (37.5) 0 2 (50.0) 0 2 (22.2) 8 (32.0)
Euphoric mood 0 4 (57.1) 3 (50.0) 7 (43.8) 0 1 (25.0) 0 1 (11.1) 8 (32.0)
Hypomagnesemia 2 (66.7) 1 (14.3) 2 (33.3) 5 (31.3) 0 2 (50.0) 1 (100.0) 3 (33.3) 8 (32.0)
Vomiting 1 (33.3) 3 (42.9) 1 (16.7) 5 (31.3) 1 (25.0) 1 (25.0) 1 (100.0) 3 (33.3) 8 (32.0)
Hypokalemia 2 (66.7) 2 (28.6) 2 (33.3) 6 (37.5) 0 1 (25.0) 0 1 (11.1) 7 (28.0)
Peripheral oedema 1 (33.3) 2 (28.6) 0 3 (18.8) 2 (50.0) 2 (50.0) 0 4 (44.4) 7 (28.0)
Weight decreased 1 (33.3) 2 (28.6) 1 (16.7) 4 (25.0) 1 (25.0) 2 (50.0) 0 3 (33.3) 7 (28.0)
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For these seven patients, median progression-free survival was
158 days (76– 198) and median overall survival was 364 days
(235–504).
DISCUSSION
In our study, the MTD and recommended phase II dose of
obatoclax as a 3-h infusion, in combination with etoposide and
carboplatin, were determined to be 30 mg daily for 3 days. As
expected, the observed DLTs consisted of CNS AEs previously
described with single-agent obatoclax infusions. Somnolence,
euphoric mood, and disorientation defined the MTD for the 3-h
infusion schedule. The majority of these AEs occurred during
obatoclax infusion and resolved shortly after the infusion ended,
and did not require any special intervention, except for the
standard observation planned in the protocol during and after the
drug infusion. There was no MTD defined for the 24-h obatoclax
infusion, and only one patient was enrolled at the highest dose
level of 60 mg (as the available information was already considered
to be adequate to choose between the two schedules).
We observed marked differences in the incidence of somnolence
in the 3-h infusion arm (75%) versus the 24-h infusion arm (0%),
and in the incidence of euphoric mood in the 3-h infusion arm
(44%) versus the 24-h infusion arm (11%). These findings agree
with those of previous studies of single-agent obatoclax in which
CNS AEs were more frequent and of higher toxicity grade with
shorter infusions of obatoclax (Schimmer et al, 2008; Hwang et al,
2010). Although no direct correlation has been shown between the
intensity of CNS symptoms and Cmax or area under the curve, these
symptoms appear to be related to the level of obatoclax exposure.
Furthermore, the presence of these symptoms indicates that the
drug is able to cross the blood– brain barrier; indeed, the CNS
toxicity may be an on-target effect resulting from inhibition of
BCL-XL expressed in neurons.
Comparison of the incidence of non-CNS AEs between the two
infusion schedules did not indicate major differences or patterns
suggestive of specific organ system toxicity. However, increased
neutropenia was observed in patients previously treated with
chemotherapy. This was likely due to the effects on the bone
marrow of prior cytotoxic therapy and not likely due to a direct
obatoclax effect, as the overall incidence of neutropenia observed
in our trial appears similar to that reported for etoposide and
carboplatin in comparable patient populations (Lara et al, 2009;
Socinski et al, 2009).
Navitoclax is another agent in development that inhibits BCL-2
family members BCL-2, BCL-XL, and BCL-W. Phase I evaluation of
single-agent navitoclax demonstrated that thrombocytopenia was
the dose-limiting AE (Gandhi et al, 2011), which is consistent with
the role shown for BCL-XL in platelet regulation (Zhang et al,
2007). Thrombocytopenia has not been a prominent finding in
single-agent phase I trials of obatoclax administered as a 3-h
(O’Brien et al, 2009) or a 24-h infusion (Schimmer et al, 2008).
Instead, two patients with myelodysplastic syndrome had marked
increases in platelets and became platelet transfusion-independent
when treated with single-agent obatoclax (Schimmer et al, 2008).
In this trial, grade 3 or 4 thrombocytopenia occurred in 33% of
the chemotherapy-naı¨ve patients. This may be a higher rate of
grade 3 or 4 thrombocytopenia than the rate of 10% reported in the
carboplatin and etoposide control arm of a recent SCLC trial
(Socinski et al, 2009); however, without a controlled trial, any
conclusions in this regard are tentative. Nevertheless, the degree of
thrombocytopenia seen with obatoclax in multiple studies appears
less than that seen with navitoclax. As plasma exposures of
navitoclax in patients treated with this agent (Gandhi et al, 2011)
are considerably higher than those achieved with obatoclax
(O’Brien et al, 2009) due to CNS-limiting events, one explanation
for the low rate of thrombocytopenia seen with obatoclax may be
that obatoclax does not achieve the concentrations in platelets
necessary to completely inhibit BCL-XL. Alternatively, it is
possible that obatoclax may not inhibit BCL-2 to the same degree
as navitoclax.
In this study, it was initially recommended that diphenhydra-
mine and an H2-blocking agent be administered before obatoclax
infusion to prevent cytokine release syndrome. Diphenhydramine
was recognised to worsen somnolence, and the recommendation
was changed to utilise prophylaxis with only an H2-blocking agent.
Thus, prophylactic treatment with diphenhydramine is no longer
recommended.
Although the study was not powered to compare the efficacy of
the two infusion schedules, the overall response rate was higher in
patients receiving the 3-h infusion compared with patients
receiving the 24-h infusion (81 vs 44%), and overall survival was
longer in the 3-h infusion cohorts. These data indicate that the 3-h
infusion schedule demonstrates promising activity and supports
utilising this schedule in future studies.
Data from an earlier study in older patients with previously
untreated acute myeloid leukemia also support the conclusion that
efficacy with the 3-h infusion of obatoclax may be increased when
Table 3 Differences in non-haematological adverse event incidence in
3-h and 24-h obatoclax infusion cohorts
3-h cohorts
n (%)
24-h cohorts
n (%)
X20% Difference in incidence of overall adverse events
3-h 4 24-h 16 (100) 9 (100)
Somnolence 12 (75) 0 (0)
Alopecia 9 (56) 3 (33)
Constipation 9 (56) 3 (33)
Euphoric mood 7 (44) 1 (11)
Dysgeusia 6 (38) 0 (0)
Hypokalemia 6 (38) 1 (11)
Ataxia 5 (31) 1 (11)
Insomnia 5 (31) 0 (0)
Abdominal pain 4 (25) 0 (0)
Cough 4 (25) 0 (0)
Non-cardiac chest pain 4 (25) 0 (0)
24-h 4 3-h
Hyponatremia 1 (6) 4 (44)
Peripheral oedema 3 (19) 4 (44)
Asthenia 2 (13) 3 (33)
Deep vein thrombosis 1 (6) 3 (33)
Hyperglycemia 0 (0) 2 (22)
Neck pain 0 (0) 2 (22)
Pain 0 (0) 2 (22)
Wheezing 0 (0) 2 (22)
X10% Difference in absolute incidence of grade 3 and 4 adverse events
3-h 4 24-h 16 (100) 9 (100)
Somnolence 5 (31) 0 (0)
Hypokalemia 4 (25) 1 (11)
Diarrhoea 2 (13) 0 (0)
Nausea 2 (13) 0 (0)
24-h 4 3-h
Hyponatremia 0 (0) 4 (44)
Deep vein thrombosis 1 (6) 2 (22)
Chronic obstructive pulmonary disease 0 (0) 1 (11)
Dyspnea 0 (0) 1 (11)
INR increased 0 (0) 1 (11)
Neck pain 0 (0) 1 (11)
Pain 0 (0) 1 (11)
Pulmonary embolism 0 (0) 1 (11)
Abbreviation: INR = International Normalised Ratio.
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compared with efficacy with the 24-h infusion (Raza et al, 2009). In
this study, 13 patients received single-agent obatoclax utilising a 3-
h infusion (3 at 20 mg m2 and 10 at 30 mg m2) and 5 received
obatoclax utilising a 24-h infusion (all at 60 mg m2), with
obatoclax administered on days 1– 3 of a 14-day cycle. Efficacy
data after cycle 2 indicated that four patients receiving a 3-h
infusion of obatoclax had a X50% decrease in bone marrow
blasts, compared with none of the patients on the 24-h schedule
of obatoclax infusion.
Analysis of pharmacodynamic endpoints in the patients in this
trial was performed as a measure of cell death and has been
reported elsewhere (Dean et al, 2011). These data indicate
that patients with radiologic, unconfirmed complete or partial
responses after two cycles of treatment (‘responders’) had a
significant increase in circulating cell death biomarkers (cleaved
cytokeratin 18 and oligonucleosomal DNA) by day 3 with both
infusion schedules, whereas nonresponders did not.
There were practical issues seen in the outpatient setting
with patients on the 24-h obatoclax infusions that were not seen
with the shorter 3-h infusions administered in the infusion suite.
Pump malfunctions at home led to the administration of less than
full doses for those patients. This difficulty provided an additional
reason to favour the 3-h obatoclax infusion schedule in
future studies.
Study limitations included the uncontrolled study design,
making it difficult to distinguish toxicity related to obatoclax
from that related to chemotherapy, and the small number of
patients enrolled. Furthermore, pharmacokinetic analyses were not
performed in this trial, so precise exposure levels at the different
dosages are not available.
Obatoclax administered as a 3-h infusion in combination with
carboplatin and etoposide was generally well tolerated at doses of
up to 30 mg per day. Although the 3-h infusion was associated with
Table 4 Grade 3 and 4 adverse events in two or more patients
3-h infusion schedule, n (%) 24-h infusion schedule, n (%) Total, n (%)
System organ class
preferred term
Obatoclax
15mg
per day
(n¼ 3)
Obatoclax
30mg
per day
(n¼ 7)
Obatoclax
45mg
per day
(n¼ 6)
Overall
(n¼16)
Obatoclax
30mg
per day
(n¼ 4)
Obatoclax
45mg
per day
(n¼ 4)
Obatoclax
60mg
per day
(n¼1)
Overall
(n¼ 9) (N¼ 25)
Neutropenia
Grade 3 0 1 (14.3) 1 (16.7) 2 (12.5) 0 1 (25.0) 0 1 (11.1) 3 (12.0)
Grade 4 3 (100.0) 4 (57.1) 3 (50.0) 10 (62.5) 4 (100.0) 2 (50.0) 1 (100.0) 7 (77.8) 17 (68.0)
Thrombocytopenia
Grade 3 1 (33.3) 2 (28.6) 1 (16.7) 4 (25.0) 0 1 (25.0) 0 1 (11.1) 5 (20.0)
Grade 4 0 2 (28.6) 1 (16.7) 3 (18.8) 0 2 (50.0) 0 2 (22.2) 5 (20.0)
Anaemia
Grade 3 0 2 (28.6) 1 (16.7) 3 (18.8) 0 2 (50.0) 0 2 (22.2) 5 (20.0)
Grade 4 0 0 1 (16.7) 1 (6.3) 0 0 0 0 1 (4.0)
Hypokalemia
Grade 3 2 (66.7) 1 (14.3) 1 (16.7) 4 (25.0) 0 1 (25.0) 0 1 (11.1) 5 (20.0)
Somnolence
Grade 3 0 3 (42.9) 2 (33.3) 5 (31.3) 0 0 0 0 5 (20.0)
Fatigue
Grade 3 1 (33.3) 0 2 (33.3) 3 (18.8) 0 1 (25.0) 0 1 (11.1) 4 (16.0)
Hyponatremia
Grade 3 0 0 0 0 1 (25.0) 2 (50.0) 0 3 (33.3) 3 (12.0)
Grade 4 0 0 0 0 1 (25.0) 0 0 1 (11.1) 1 (4.0)
Deep vein thrombosis
Grade 3 0 1 (14.3) 0 1 (6.3) 0 2 (50.0) 0 2 (22.2) 3 (12.0)
Leukopenia
Grade 3 0 1 (14.3) 1 (16.7) 2 (12.5) 0 0 0 0 2 (8.0)
Grade 4 0 1 (14.3) 0 1 (6.3) 0 0 0 0 1 (4.0)
Diarrhoea
Grade 3 0 1 (14.3) 1 (16.7) 2 (12.5) 0 0 0 0 2 (8.0)
Nausea
Grade 3 0 2 (28.6) 0 2 (12.5) 0 0 0 0 2 (8.0)
Table 5 Efficacy in intent-to-treat population
Complete
or partial
response,
n (%)a
Median
PFS, days
(95% CI)
Median OS,
days
(95% CI)
3-h infusion (n¼ 16) 13 (81)b 184.5 (136–203) 379 (246–504)
24-h infusion (n¼ 9) 4 (44) 181 (43–203) 283 (80–393)
All patients (n¼ 25) 17 (68) 182 (158–198) 312 (246–393)
Abbreviations: CI¼ confidence interval; OS¼ overall survival; PFS¼ progression-free
survival. aAll responses were confirmed by a second evaluation at least 4 weeks later.
bIncludes two complete responses.
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a higher incidence of some (particularly CNS) AEs than the 24-h
infusion, preliminary data indicate it may also be associated with
improved efficacy compared with obatoclax as a 24-h infusion.
In consideration of these preliminary efficacy findings, as well as
practical issues with the 24-h infusion arm, 3-h infusions of
obatoclax with carboplatin and etoposide are recommended for
use in future clinical trials in patients with SCLC.
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